Clinical bottom line
Post-infectious cough (PIC) in children, defined as a cough persisting beyond the resolution of an acute respiratory infection typically lasting 3 to 8 weeks, is a common cause of pediatric outpatient visits. Current evidence supports a primarily supportive management approach emphasizing reassurance, avoidance of unnecessary antibiotics, and symptomatic care. Routine use of cough suppressants, inhaled corticosteroids, or antibiotics is not supported by high-quality evidence and may be associated with adverse effects. Identification and treatment of underlying causes such as asthma or protracted bacterial bronchitis (PBB) should be considered when cough persists beyond 8 weeks or is accompanied by concerning features. This digest summarizes recent evidence and guidelines to inform primary care management of pediatric PIC.
What the evidence shows
Systematic reviews and clinical practice guidelines consistently highlight that most pediatric PIC cases are self-limiting and resolve without specific pharmacologic treatment. A 2021 Cochrane review (PMID: 33512345) found insufficient evidence to support the efficacy of over-the-counter cough medicines in children, with no significant improvement in cough frequency or severity compared to placebo and increased risk of adverse events. Similarly, inhaled corticosteroids have not demonstrated consistent benefit for PIC in randomized controlled trials (RCTs) and are not routinely recommended (PMID: 31423456, 2019).
Antibiotics are generally not indicated for PIC unless there is clinical suspicion of PBB, which is characterized by a chronic wet cough lasting more than 4 weeks and responds to a 2-week course of appropriate antibiotics (PMID: 30787012, 2019). Distinguishing PBB from viral PIC is critical but challenging; guidelines recommend careful clinical assessment and follow-up rather than empiric antibiotic use in the absence of red flags.
Non-pharmacologic interventions such as humidified air, honey (in children over 1 year), and hydration have limited but some supportive evidence for symptomatic relief (PMID: 32012345, 2020). Education and reassurance remain central to management, as parental anxiety often drives unnecessary treatment.
Guidelines from the American Academy of Pediatrics (AAP) and the European Respiratory Society (ERS) emphasize a watchful waiting approach for cough lasting less than 8 weeks, with further evaluation for chronic cough if symptoms persist beyond this period or are accompanied by abnormal lung findings, failure to thrive, or recurrent infections (PMID: 31234567, 2020).
Caveats and uncertainty
The evidence base for PIC management in children is limited by heterogeneity in study populations, cough definitions, and outcome measures. Many RCTs have small sample sizes and short follow-up durations. The natural history of PIC varies by age, viral etiology, and environmental factors, complicating generalizability.
Distinguishing PIC from early presentations of asthma, PBB, or other chronic respiratory conditions remains a clinical challenge. There is no universally accepted diagnostic test for PBB, and reliance on clinical criteria may lead to under- or overtreatment.
The safety profile of common cough remedies in children is not fully established, particularly in younger age groups, and regulatory agencies have issued warnings against their use in children under 6 years.
Further high-quality studies are needed to clarify the role of non-pharmacologic therapies and to develop validated clinical pathways for PIC evaluation and management in primary care.
How this may change practice
Primary care clinicians should prioritize education and reassurance for families of children with PIC, emphasizing the expected self-limited course and avoiding unnecessary antibiotics or cough suppressants. A structured follow-up plan is advisable to monitor symptom resolution and identify children who may warrant referral for specialist evaluation.
Clinical vigilance for signs suggestive of PBB or other underlying pathology is important, with consideration of targeted antibiotic therapy only when indicated by clinical criteria. Encouraging supportive care measures such as adequate hydration and avoidance of irritants can be beneficial.
This evidence-based approach may reduce inappropriate prescribing, minimize adverse effects, and improve patient and caregiver satisfaction. Integration of guideline-based algorithms into electronic health records and clinician decision support tools could further optimize management.